rier to disease eradication by TKIs.71 We contend that eradicating CML will Elvitegravir EVG require targeting the stem cell niche. Several pathways have emerged as potential targets, and a clear winner has not yet been identified. In many respects, CML has served as a paradigm for cancer therapy, and it is likely that this will continue to be the case as we start to transform profound responses into definitive ,cures.,Acknowledgments Funding The authors are supported by NIH grants HL082978-01 , CA04963920A2 , and CA129528 , the Leukemia and Lymphoma Society grant 7036-01. D.W.W. was supported in part by a grant to the University of Utah from the Howard Hughes Medical Institute through the Med into Grad Initiative. M.W.D. is a Scholar in Clinical Research of the Leukemia and Lymphoma Society. References 1.
Kantarjian H, O,Brien S, Jabbour E, et al. Impact of Treatment End Point Definitions on Perceived Differences in Long-Term Outcome With Tyrosine Kinase Inhibitor Therapy in Chronic EX 527 49843-98-3 Myeloid Leukemia. J Clin Oncol. 2011 Woessner et al. Page 9 Cancer J. Author manuscript, available in PMC 2012 May 1. NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript 2. Signorovitch JE, Wu EQ, Betts KA, et al. Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. Curr Med Res Opin. 2011, 27:1263�?1. 3. Tauchi T, Kizaki M, Okamoto S, et al. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res.
2011, 35:585�?0. 4. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983, 306:277�?0. 5. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973, 243:290�?. 6. Anafi M, Gazit A, Gilon C, Ben-Neriah Y, Levitzki A. Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins. J Biol Chem. 1992, 267:4518�?3. 7. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001, 344:1031�?. 8.
National Cancer Institute. National Institutes of Health. Surveillance Epidemiology and End Results web site. seer.cancer.gov/statfacts/html/cmyl.html 9. Vardiman JW, Harris NL, Brunning RD. The World Health Organization classification of the myeloid neoplasms. Blood. 2002, 100:2292�?02. 10. Chronic granulocytic leukaemia: comparison of radiotherapy and busulphan therapy. Report of the Medical Research Council,s working party for therapeutic trials in leukaemia. Br Med J. 1968, 1:201�?. 11. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood. 1993, 82:398�?07. 12. Rushing D, Goldman A, Gibbs G, Howe R, Kennedy BJ.
Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia. Am J Clin Oncol. 1982, 5:307�?3. 13. Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data metaanalysis of three randomized trials. Chronic myeloid leukemia trialists, collaborative group. Br J Haematol. 2000, 110:573�?. 14. Pavlu J, Szydlo RM, Goldman JM, Apperley JF. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood. 2011, 117:755�?3. 15. Breccia M, Palandri F, Iori AP, et al. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplanta